Xu Xiaomin, Xu Jiajun, Li Chuanwei, Wang Gang, Wang Wenzhe, Ye Yujian, Chen Yong, Liu Tieqiao, Zhao Min, Wang Xuyi, Zhong Na, Jiang Haifeng
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mental Health Centre, West China Hospital, Sichuan University, Chengdu, China.
BJPsych Open. 2022 Oct 18;8(6):e188. doi: 10.1192/bjo.2022.589.
Benzodiazepine receptor agonists (BZRAs) are commonly used clinically and data on their hazardous use from large populations of psychiatric patients is limited.
To assess the current status of hazardous BZRA use and related factors in Chinese out-patient psychiatric settings.
The study included out-patients with at least one BZRA prescription from five psychiatric settings in east, central and west China in 2018. Demographic and prescription information were extracted from the electronic prescription database. We defined the co-occurrence of overdose and long-term use as hazardous use, and patients whose recorded diagnoses did not meet any indications approved by the Chinese Food and Drug Administration as over-indication users. Additionally, 200 hazardous users were randomly selected for follow-up interview to confirm the actual situation.
Among 720 054 out-patients, 164 450 (22.8%) had at least one BZRA prescription; 55.9% of patients were prescribed over-indication and 3% were defined as hazardous users. Multilevel multivariate regression analysis with hospital as a random effect showed that factors associated with hazardous use were older age (18-64 years: β = 0.018; 95% CI 0.013-0.023; >65 years: β = 0.015; 95% CI 0.010-0.021), male (β = 0.005, 95% CI 0.003-0.007), over-indication (β = 0.013, 95% CI 0.012-0.015), more out-patient visits (β = 0.006, 95% CI 0.006-0.006) and more visits to different doctors (β = 0.007, 95% CI 0.007-0.008); 98.5% of hazardous users (197/200) could not be contacted.
BZRAs are commonly used and there is a relatively large proportion of over-indication users among Chinese psychiatric out-patients. However, only a small proportion of hazardous users were detected. The study highlights how to use prescription data to support improvements in clinical practice.
苯二氮䓬受体激动剂(BZRAs)在临床上常用,而来自大量精神科患者群体的其有害使用数据有限。
评估中国精神科门诊环境中BZRA有害使用的现状及相关因素。
该研究纳入了2018年来自中国东部、中部和西部五个精神科机构的至少有一张BZRA处方的门诊患者。从电子处方数据库中提取人口统计学和处方信息。我们将过量使用和长期使用同时出现定义为有害使用,将记录的诊断不符合中国食品药品监督管理局批准的任何适应症的患者定义为超适应症使用者。此外,随机选择200名有害使用者进行随访访谈以确认实际情况。
在720054名门诊患者中,164450名(22.8%)至少有一张BZRA处方;55.9%的患者被超适应症用药,3%被定义为有害使用者。以医院为随机效应的多水平多变量回归分析显示,与有害使用相关的因素包括年龄较大(18 - 64岁:β = 0.018;95%置信区间0.013 - 0.023;>65岁:β = 0.015;95%置信区间0.010 - 0.021)、男性(β = 0.005,95%置信区间0.003 - 0.007)、超适应症(β = 0.013,95%置信区间0.012 - 0.015)、门诊就诊次数更多(β = 0.006,95%置信区间0.006 - 0.006)以及看不同医生的次数更多(β = 0.007,95%置信区间0.007 - 0.008);98.5%的有害使用者(197/200)无法联系上。
BZRAs被广泛使用,中国精神科门诊患者中超适应症使用者比例相对较大。然而,仅检测到一小部分有害使用者。该研究凸显了如何利用处方数据来支持临床实践的改进。